Next Article in Journal
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB
Next Article in Special Issue
New Insights into the Pathophysiology and Treatment of Fibromyalgia
Previous Article in Journal
Functionalisation of Polyvinylpyrrolidone on Gold Nanoparticles Enhances Its Anti-Amyloidogenic Propensity towards Hen Egg White Lysozyme
Previous Article in Special Issue
Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
Open AccessFeature PaperReview

Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology

by Sanam Kia 1,* and Ernet Choy 2
1
Abertawe Bro Morgannwg University Health Board NHS Trust, Neath Port Talbot Hospital, Port Talbot, Wales SA12 7BX, UK
2
Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff University, Tenovus Building, Heath Park, Cardiff CF14 4XN, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Kim Lawson
Biomedicines 2017, 5(2), 20; https://doi.org/10.3390/biomedicines5020020
Received: 23 February 2017 / Revised: 20 April 2017 / Accepted: 26 April 2017 / Published: 8 May 2017
(This article belongs to the Special Issue Drug Therapies for the Treatment of Fibromyalgia)
Fibromyalgia syndrome (FMS) is a chronic condition with unknown aetiology. The pathophysiology of the disease is incompletely understood; despite advances in our knowledge with regards to abnormal central and peripheral pain processing, and hypothalamo–pituitary–adrenal dysfunction, there is no clear specific pathophysiological therapeutic target. The management of this complex condition has thus perplexed the medical community for many years, and several national and international guidelines have aimed to address this complexity. The most recent guidelines from European League Against Rheumatism (EULAR) (2016), Canadian Pain Society (2012), and The Association of the Scientific Medical Societies in Germany (AWMF) (2012) highlight the change in attitudes regarding the overall approach to FMS, but offer varying advice with regards to the use of pharmacological agents. Amitriptyline, Pregabalin and Duloxetine are used most commonly in FMS and though modestly effective, are useful adjunctive treatment to non-pharmaceutical measures. View Full-Text
Keywords: fibromyalgia syndrome (FMS); guideline; pharmacology; therapy fibromyalgia syndrome (FMS); guideline; pharmacology; therapy
MDPI and ACS Style

Kia, S.; Choy, E. Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. Biomedicines 2017, 5, 20.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop